Pharmaceuticals Saudi Arabia

Saudi Arabia Insulin Biosimilars Market Analysis, 2024–2034

Saudi Arabia Insulin Biosimilars Market Industry Trends and Forecast to 2034: Segmented by (Type, Delivery, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Saudi Arabia · 2024–2034 · estimates

Values shown here are estimates. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $58.5 Mn Estimated value
Estimate 2025 $67.4 Mn 1.5% of the global market
Projected 2034 $240.9 Mn 257.3% Adds $173.5 Mn over 9 forecast years
CAGR 2025–2034 15.2% Faster than 73% of 180 Pharmaceuticals markets here
Key players 6 +1
  • Saudi Arabia is 1.53% of the global market.
  • In Middle East, the largest is Saudi Arabia (this report) at $67.4 Mn.
  • Fastest growing: Saudi Arabia (this report) at 15.2% a year.
  • Saudi Arabia ranks 1st of 2 by size in Middle East.

Market size projection

Saudi Arabia

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$173.5 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Insulin Biosimilars Market market size by year, Saudi Arabia
YearMarket sizeChange that yearSince 2025
2024 (estimate) $58.5 Mn — —
2025 (base) $67.4 Mn +$8.9 Mn —
2026 (forecast) $77.7 Mn +$10.2 Mn +15.2%
2027 (forecast) $89.5 Mn +$11.8 Mn +32.7%
2028 (forecast) $103.1 Mn +$13.6 Mn +52.9%
2029 (forecast) $118.7 Mn +$15.7 Mn +76.1%
2030 (forecast) $136.8 Mn +$18.0 Mn +102.9%
2031 (forecast) $157.6 Mn +$20.8 Mn +133.7%
2032 (forecast) $181.5 Mn +$24.0 Mn +169.3%
2033 (forecast) $209.1 Mn +$27.6 Mn +210.2%
2034 (forecast) $240.9 Mn +$31.8 Mn +257.3%

Estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Same market worldwide

By geography

  1. Global $4.42 Bn
  2. North America $2.25 Bn
  3. US $1.56 Bn
  4. Europe $872.6 Mn
  5. APAC $865.7 Mn
  6. Canada $340.0 Mn
  7. China $324.4 Mn
  8. Japan $263.0 Mn
  9. Latin America $210.3 Mn
  10. Middle East $183.0 Mn
  11. Germany $133.9 Mn
  12. France $125.8 Mn
  13. Brazil $113.9 Mn
  14. UK $104.7 Mn
  15. Italy $100.0 Mn
  16. Ecuador $91.2 Mn
  17. Spain $72.3 Mn
  18. India $75.6 Mn
  19. Saudi Arabia (this report) $67.4 Mn
  20. Africa $61.6 Mn
  21. Mexico $59.8 Mn
  22. Australia $49.9 Mn
  23. New Zealand $45.9 Mn
  24. Russia $42.0 Mn
  25. South Africa $28.9 Mn
  26. UAE $20.1 Mn
  27. Egypt $12.2 Mn
  28. Philippines $11.1 Mn
  29. Malaysia $7.7 Mn
  30. Hong Kong $6.5 Mn
  31. Thailand $5.2 Mn
  32. Singapore $4.8 Mn
  33. Kenya $3.2 Mn

The Saudi Arabia Insulin Biosimilars Market Analysis Executive Summary

Insulin biosimilars are lower-cost versions of branded insulins that work the same way, improving access to diabetes treatment.

Key segments of the insulin Biosimilars market include type (Long-Acting, Rapid-Acting and Premixed) and delivery (Vials, Pens and Cartridges).

Saudi Arabia Insulin Biosimilars Market Dynamics

Market Growth Drivers

Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the insulin Biosimilars market. Wider insurance coverage and more doctors trained in obesity care are adding to demand.

Opportunity

Oral formulations, combination therapies and use in heart, kidney and liver disease open new growth paths for the insulin Biosimilars market, especially in fast-growing emerging economies.

Market Restraints

High treatment prices, limited reimbursement, supply shortages and side effects that lead some patients to stop treatment hold back the insulin Biosimilars market. Long-term safety data and lifestyle support are still needed for many patients.

Competitive Landscape for Insulin Biosimilars Market in Saudi Arabia

The insulin Biosimilars market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Insulin Biosimilars Market in Saudi Arabia

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for insulin Biosimilars. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Saudi Arabia.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Insulin Biosimilars right now, from free public sources.

Latest research 35 papers since 2021 (worldwide)

  1. Making Modern Diabetes Medications Affordable and Accessible: Lessons From India for Other Countries. Diabetes care, 2026
  2. New Insulins, Biosimilars, and Insulin Therapy. Diabetes technology & therapeutics, 2026
  3. Measuring the Impact of the Substitution of Innovator Biologics With Biosimilars on Uptake and Costs Among Ontario Public Drug Benefit Recipients. Clinical pharmacology and therapeutics, 2026
  4. Factors Accounting for Pharmacodynamic Variability of Basal Insulin Preparations in Euglycemic Clamp Settings in Healthy Individuals. Clinical pharmacokinetics, 2025
  5. Innovative approach to support therapeutic proteins' similarity in hydrodynamic size using high-throughput dynamic light scattering and forced degradation. Scientific reports, 2025
Search all of them on PubMed (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, WHO Global Health Observatory, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Insulin Biosimilars in context

Saudi Arabia compared

  • Diabetes (adults, WHO): 20.8% of adults (2022). World: 14.1% of adults (2022). 5th highest of the 9 countries we cover in Middle East.[1]
  • Health spending per person: 1,825 US$ per person (2023). World: 1,317 US$ per person (2023). 2nd highest of the 9 countries we cover in Middle East.[2]
  • Doctors: 3.41 per 1,000 people (2023). World: 1.86 per 1,000 people (2022). Highest of the 9 countries we cover in Middle East.[3]

Questions, answered with public data

How much research is published on Insulin Biosimilars?
PubMed lists 35 papers added since January 2021 that match this market, worldwide.[4]
What does WHO report for Saudi Arabia?
Diabetes (adults, WHO): 20.8 % of adults in 2022, the latest WHO figure.[1]
How many people in Saudi Arabia are 65 or older?
3.1% of people were 65 or older in 2025.[5]

[1] WHO Global Health Observatory, Diabetes (adults, WHO) (% of adults). Retrieved 14 Nov 2026.

[2] World Bank Open Data, Health spending per person (US$ per person). Retrieved 13 Nov 2026.

[3] World Bank Open Data, Doctors (per 1,000 people). Retrieved 13 Nov 2026.

[4] PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.

[5] World Bank Open Data, Population ages 65 and above (% of total population), from UN population estimates. Retrieved 13 Nov 2026.

Free data on this topic

Get a free sample The table of contents and sample pages. No payment needed. Request sample Consult Us Questions about Insulin Biosimilars in Saudi Arabia? Our analysts can size it for your plan. Talk to us See the public data Diabetes (adults, WHO) for every country, free. Open the Public Health Dashboard

From our blog

Wound Care: Advanced Dressings for Faster HealingNearly 15% of US Medicare beneficiaries, 8.2 million people, had a wound or wound infection in one year… Patient Support Programmes: Helping Patients Stay on TreatmentWHO says only about half of patients in developed countries take long-term medicines as prescribed. Patient… Insulin Delivery Devices: Pens, Pumps and BeyondOver 9.5 million people live with type 1 diabetes and need insulin every day. How delivery devices are…
Back to Catalogue
Keep exploring

Related Pharmaceuticals reports in Saudi Arabia

See all
Same topic, other categories

Related on diabetes and biologics and biosimilars

See the topic